Published in Proc Natl Acad Sci U S A on January 31, 2011
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discov (2016) 2.16
Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog (2012) 1.91
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A (2012) 1.51
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med (2016) 1.47
Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adh Migr (2012) 1.41
The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng (2014) 1.40
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res (2012) 1.24
Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia (2013) 1.11
Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt (2012) 1.08
AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One (2013) 1.03
Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng (2012) 1.00
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation. PLoS One (2012) 0.98
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol (2015) 0.96
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Cationic nanoparticles have superior transvascular flux into solid tumors: insights from a mathematical model. Ann Biomed Eng (2012) 0.95
Magnetic targeting of nanoparticles across the intact blood-brain barrier. J Control Release (2012) 0.95
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther (2013) 0.95
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
A New Imaging Platform for Visualizing Biological Effects of Non-Invasive Radiofrequency Electric-Field Cancer Hyperthermia. PLoS One (2015) 0.93
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release (2013) 0.92
Stromal matrix metalloprotease-13 knockout alters Collagen I structure at the tumor-host interface and increases lung metastasis of C57BL/6 syngeneic E0771 mammary tumor cells. BMC Cancer (2013) 0.91
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano (2014) 0.91
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PLoS One (2015) 0.91
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Theranostics (2015) 0.89
The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Phila) (2013) 0.88
Challenges to effective cancer nanotheranostics. J Control Release (2012) 0.87
Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy. Front Oncol (2015) 0.86
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett (2013) 0.85
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release (2013) 0.85
Tumor-associated macrophages and stromal TNF-α regulate collagen structure in a breast tumor model as visualized by second harmonic generation. J Biomed Opt (2013) 0.84
Obesity and Cancer: An Angiogenic and Inflammatory Link. Microcirculation (2016) 0.84
Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. J Thorac Oncol (2014) 0.84
Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin β3-subunit deficient mice. PLoS One (2012) 0.83
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Control Release (2015) 0.83
How fibrosis influences imaging and surgical decisions in pancreatic cancer. Front Physiol (2012) 0.82
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J (2015) 0.81
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells. Hypertension (2016) 0.80
The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer. Oncotarget (2014) 0.80
The solid mechanics of cancer and strategies for improved therapy. J Biomech Eng (2016) 0.79
Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol (2012) 0.79
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release (2015) 0.79
Cancer: Tumour-fighting virus homes in. Nature (2011) 0.79
Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. Oncoimmunology (2012) 0.79
Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? Future Virol (2013) 0.79
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Matrix Biol (2015) 0.79
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner. Sci Rep (2017) 0.78
G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer? Front Pharmacol (2015) 0.78
Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. Front Oncol (2015) 0.78
Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors. Cancer Res (2015) 0.78
Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J Control Release (2014) 0.78
Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy. Mol Cell Ther (2014) 0.78
Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors. Mol Cancer (2015) 0.78
Exploring the tumor microenvironment with nanoparticles. Cancer Treat Res (2015) 0.77
Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and Implications for Cancer Therapy. Neoplasia (2016) 0.77
Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment. Mol Pharm (2016) 0.76
Promising oncolytic agents for metastatic breast cancer treatment. Oncolytic Virother (2015) 0.76
Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy. J Control Release (2017) 0.76
A functional nanocarrier that copenetrates extracellular matrix and multiple layers of tumor cells for sequential and deep tumor autophagy inhibitor and chemotherapeutic delivery. Autophagy (2016) 0.75
Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal. Ther Clin Risk Manag (2015) 0.75
Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget (2016) 0.75
Targeting gallbladder cancer: hyaluronan sensitizes cancer cells to chemo-therapeutics. Int J Clin Exp Pathol (2015) 0.75
Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy. Expert Opin Drug Deliv (2016) 0.75
Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma. Transl Oncol (2016) 0.75
Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy. Oncotarget (2016) 0.75
The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget (2017) 0.75
Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts. Lab Invest (2016) 0.75
Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100 nm Particles. Mol Ther (2016) 0.75
The Use of Second Harmonic Generation to Image the Extracellular Matrix During Tumor Progression. Intravital (2015) 0.75
MR Imaging Biomarkers in Oncology Clinical Trials. Magn Reson Imaging Clin N Am (2016) 0.75
Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid. Front Oncol (2015) 0.75
Tumor Stiffening, a Key Determinant of Tumor Progression, is Reversed by Nanomaterial-Induced Photothermal Therapy. Theranostics (2017) 0.75
TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC. Oncotarget (2017) 0.75
The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice. Cancers (Basel) (2016) 0.75
Vascular normalization in cerebral angiogenesis: friend or foe? Methods Mol Biol (2014) 0.75
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. PLoS One (2017) 0.75
Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids. Sci Rep (2016) 0.75
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene (2016) 0.75
A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix. Sci Rep (2016) 0.75
Angiotensin II inhibitor facilitates epidermal wound regeneration in diabetic mice. Front Physiol (2015) 0.75
Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer. Sci Rep (2017) 0.75
Enhancing Tumor Penetration of Nanomedicines. Biomacromolecules (2017) 0.75
Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. World J Surg (2017) 0.75
Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy. Biomaterials (2017) 0.75
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells. Front Pharmacol (2017) 0.75
Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer (2017) 0.75
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res (2000) 4.89
Molecular mechanisms of drug resistance. J Pathol (2005) 4.60
Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev (2003) 3.87
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet (1998) 3.41
Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J (2002) 3.25
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev (2006) 3.14
Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A (2001) 2.96
Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation (2005) 2.55
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 2.35
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol (2003) 2.16
Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab (2005) 2.13
Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int (2006) 2.12
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens (2005) 2.04
Extravascular diffusion in normal and neoplastic tissues. Cancer Res (1984) 2.04
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension (2009) 1.85
TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest (2010) 1.65
The renin-angiotensin system and malignancy. Carcinogenesis (2008) 1.62
Angiotensin receptor antagonists: focus on losartan. Lancet (1995) 1.61
Angiotensin inhibition and malignancies: a review. J Hum Hypertens (2009) 1.59
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A (2009) 1.43
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst (2006) 1.40
Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res (2002) 1.37
Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas (1987) 1.32
Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res (2007) 1.29
Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation (1994) 1.28
Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J (2010) 1.25
Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis (2005) 1.24
Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg (2007) 1.22
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res (2007) 1.18
Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res (1993) 1.12
Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res (1993) 1.09
Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res (2010) 1.08
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev (2010) 1.06
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep (2009) 1.01
Effects of angiotensin II subtype 1 receptor blockade by losartan on tubulointerstitial lesions caused by hyperoxaluria. J Urol (2002) 1.00
Clinical pharmacokinetics of losartan. Clin Pharmacokinet (2005) 0.93
Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol (2009) 0.91
Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol (2004) 0.90
ACE inhibitor bulks up muscle. Nat Med (2007) 0.82
Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-beta in experimental acute pyelonephritis. J Urol (2000) 0.81
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol (2004) 4.16
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J (2002) 3.25
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 3.13
The role of nitric oxide in tumour progression. Nat Rev Cancer (2006) 3.08
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 2.67
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A (2010) 2.62
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc (2007) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 2.29
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature (2004) 2.22
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng (2011) 2.17
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res (2003) 2.12
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10
In vivo wide-area cellular imaging by side-view endomicroscopy. Nat Methods (2010) 2.10
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood (2005) 1.98
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS One (2009) 1.92
Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol (2007) 1.89
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A (2011) 1.88
Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods (2010) 1.88
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res (2010) 1.84
A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 1.84
Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci U S A (2011) 1.84
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther (2008) 1.83
Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. Blood (2011) 1.82
Differential transplantability of tumor-associated stromal cells. Cancer Res (2004) 1.78
Polycyclic aromatic hydrocarbons: environmental pollution and bioremediation. Trends Biotechnol (2002) 1.77
Imaging angiogenesis and the microenvironment. APMIS (2008) 1.77
Robust 3-D modeling of vasculature imagery using superellipsoids. IEEE Trans Med Imaging (2007) 1.76
Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 1.73
Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res (2004) 1.72
Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat Rev Cancer (2012) 1.72
A mathematical model of murine metabolic regulation by leptin: energy balance and defense of a stable body weight. Cell Metab (2009) 1.72
Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem (2001) 1.72